Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines.

Amano, Masayuki; Ichikawa, Yasuko; Uemura, Yukari; Matsumoto, Shota; Maeda, Kenji; Matsushita, Shuzo; Shimada, Shinya; Mitsuya, Hiroaki

Amano, Masayuki; Ichikawa, Yasuko; Uemura, Yukari; Matsumoto, Shota; Maeda, Kenji; Matsushita, Shuzo; Shimada, Shinya; Mitsuya, Hiroaki.

Afiliación

Amano M; Department of Clinical Retrovirology, Joint research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Electronic address: mamano@kumamoto-u.ac.jp.
Ichikawa Y; Kumamoto General Hospital, Japan Community Health Care Organization, Kumamoto, Japan.
Uemura Y; Department of Data Sciences, Center for Clinical Sciences, National Center for Global Health and Medicine (NCGM), Tokyo, Japan.
Matsumoto S; Kumamoto General Hospital, Japan Community Health Care Organization, Kumamoto, Japan.
Maeda K; Department of Refractory Viral Infections, NCGM Research Institute, Tokyo, Japan.
Matsushita S; Department of Clinical Retrovirology, Joint research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Shimada S; Kumamoto General Hospital, Japan Community Health Care Organization, Kumamoto, Japan.
Mitsuya H; Department of Refractory Viral Infections, NCGM Research Institute, Tokyo, Japan.

J Infect ; 86(5): e130-e132, 2023 05.

Article en En | MEDLINE | ID: mdl-36736492

Asunto(s)

Vacunas contra la COVID-19; COVID-19; Humanos; COVID-19/prevención & control; Anticuerpos Antivirales; Anticuerpos Neutralizantes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Humans Idioma: En Revista: J Infect Año: 2023 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google